Navigation Links
Study suggests existing drugs may be useful in treating brain tumors
Date:10/16/2007

Oct. 15, 2007 -- Scientists have shown how developing brain tumors can turn an encounter with a signaling molecule from a fatal experience for the tumor cells into a cue for their own growth and multiplication.

Researchers at Washington University School of Medicine in St. Louis found the transformation relies on at least two other molecules that can be modified with existing drugs, opening the possibility that they may be able to use the established drugs to treat brain tumors.

The study, reported in Cancer Research, was conducted in a mouse model of neurofibromatosis type 1 (NF1), a genetic condition that leads to the development of benign and malignant tumors.

"In addition to opening up several new, exciting possibilities for brain tumor treatment both in NF1 and generally, this research is leading to what could be a very important set of insights into fundamental mechanisms of tumor formation," says the paper's senior author, Joshua Rubin, M.D., Ph.D., assistant professor of pediatrics, neurology and of neurobiology.

Rubin studies general pediatric brain tumor development. His colleague and co-author David H. Gutmann, M.D., Ph.D., the Donald O. Schnuck Family Professor of Neurology, specializes in NF1 research and directs the University's Neurofibromatosis Center, where the research took place.

The signaling molecule that scientists studied, CXCL12, binds to a receptor called CXCR4 on the surfaces of brain cells. Other researchers first identified CXCR4 while searching for receptors targeted by HIV during infection. Initially, they assumed that CXCR4's primary responsibility was controlling the movement of immune system cells. However, when they genetically disabled the receptor in mice, it had catastrophic effects on organ systems throughout the body. Further study showed the receptor was associated not only with cell movement but also with cell survival and replication.

"All of those things are also changed in cancers: canc
'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University in St. Louis
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Rural Canadians travel far for specialists: study
2. A new study surpasses Gene Therapy Hurdle
3. Tomato Sauce reduces Cancer Risk- Study
4. A question on study of Adult Stem Cell
5. Study on obesity and heart failure
6. National Lung Study in the process
7. Marijuana gateway theory strengthened by study of twins
8. Old theory of adaptation confirmed by new study
9. Study casts doubt on keyboard ills
10. Gene study links endometriosis, infertility
11. Study reveals how stress can make you sick

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)..., DALLAS,Nov.27/PRNewswire-USNewswire/--Conside...y25yearsago,solidorgantransplantationisnowalife-sa...andwomenwhogatheredattheWinspearOperaHouseinDallas...ndtheworldtocelebratethe25thanniversaryofBaylorReg...olidorgantransplantintheUnitedStates. ,, Itwas2...
(Date:11/27/2009)... , ROCHESTER, N.Y., Nov. 27 /PRNewswire-USNe... health care provider and fortunately every year, ...prevention. But do all vaccines boost immunity for...ditional ,booster shots, needed to keep immunity s..., the Journal of the American Academy of Pediatric...
(Date:11/27/2009)... , KIBBUTZ SHAMIR, Israel, Nov. 27 /PRNewswir...aq: SHMR ) ( "Shamir" ), a leading provider of in... lens market, announced today that its board of di... aggregate amount of US$ 10 million (approximately...representative rate of exchange), or approximately...
(Date:11/27/2009)...king and cycling plus low-emission vehicles may re... , FRIDAY, Nov. 27 (HealthDay News) -- Encour... using cars would offer much greater public health...cles, U.K. researchers have found. , The study ...lternative urban land transport scenarios for Lond...
(Date:11/27/2009)..., SEATTLE,Nov.27/PRNewswire/-- Allrecipes.com ...vingtrafficnumbers,withmorethan2.8millionvisitorst...atwasservedonthebiggestfoodholidayoftheyear.Theave...perserving,a5percentincreasefromlastyear,sfeast.Ac...heshowasthemostpopularThanksgivingrecipe,acontrast...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Why Some Vaccines May Require A Booster 2Health News:Why Some Vaccines May Require A Booster 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3
...bivalirudin (Angiomax) that beats the standard com...nary syndromes such as heart// attacks. This new b...uffering from acute coronary syndromes. The ...nal of Medicine. The Medicines Company and Nycome...
... in a Farm in South Korea, killing around 6,000 ch... more, South Korea’s Farm// Ministry officials sai...ference, Kim Chang-sub, a top official at the Mini...s of our testing should be known on 25th of Novemb...
...e sale of turbot after they detected high levels o...ing’s fish markets, reports the Chinese media. The...pe in 1992. Due to low resistance to disease...n, Liaoning and Xi'an have started inspections aft...
...s grouped the five major cities Vancouver//, Calga...ods, based on five features namely income, educa...one-parent families. It also observes neighb...streets, public transportation, and how well peopl...
...ert with sophisticated transgenic technologies, //...rst time created three-dimensional, time-lapse mov... live tumor tissues. In recorded experiments, immu...his new view of the body’s on-board defenses again...
... had to be hospitalized following cosmetic injecti...an cosmetic product that was unlicensed. The injec...es greater than the lethal dose for humans, report...ogists. Four persons including a doctor had to ...
Other Medicine News:Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2Health News:Health Of Residents Is Affected by Various Factors 2Health News:Innovative Movies Show Real-Time Immune-Cell Activity within Tumors 2Health News:Innovative Movies Show Real-Time Immune-Cell Activity within Tumors 3
(Date:11/27/2009)...TON, Minn, Nov. 27 ACUO TECHNOLOGI...anagement software, data migration tools and servi... Patent and Trademark Office has approved a patent...thin a Computer Network." Acuo Technologies is ple...tellectual property. In general, the granted paten...
(Date:11/25/2009)...A PARK, Calif., Nov. 25 Praxis Ele...ngs in the American Academy of Family Physicians, ...ser Satisfaction Survey for improving medical qual...ll critical for new ARRA Stimulus legislation. Pra...EMR had a positive effect in determining their sal...
(Date:11/25/2009)...ORD, Mass., Nov. 25 Holo...), a leading developer, manufacturer and supplier ...d surgical products dedicated to serving the healt...of the Radiological Society of North America (RSNA...gh December 3, 2009 to highlight our new SecurView...
Breaking Medicine Technology:Acuo Technologies Announces Patent for Asset Communication Format Within a Computer Network 2Praxis EMR Wins Top Rankings in 2009 AAFP EHR User Satisfaction Survey 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 2New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 3New Hologic SecurView(R) DX Diagnostic Workstation Software Streamlines Workflow, Improves Radiologist Productivity 4Drug Combo May Offer Best Relief for Nerve Pain 58527 1Drug Combo May Offer Best Relief for Nerve Pain 58527 2Australian study sheds light on kidney repair and disease 10181 1Australian study sheds light on kidney repair and disease 10181 2Cardinal Health Foundation Invites Health Care Providers to Apply for 241 Million in Grants to Improve Efficiency Quality of Care 58524 1Cardinal Health Foundation Invites Health Care Providers to Apply for 241 Million in Grants to Improve Efficiency Quality of Care 58524 2
...ee large PEGINTRON(TM) clinical studies address ke...OPENHAGEN, Denmark, April 27 Schering-Plough Corp...esults of three large PEGINTRON(TM) (peginterferon...estions in the hepatitis C research community and ...udies, involving a total of more than 2,700 patien...
...s $10 million milestone payment to Pharmasset , ,...aq: VRUS ) and Roche (Roche SWX: RO, ROG; Pink S...nt has been dosed in a Phase IIb study of R7128, t...n development for the treatment of chronic hepatit...uration of treatment of R7128 in combination with ...
Other Medicine Technology:Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 2Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 3Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 4Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 5Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 6Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 7Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 8Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 9Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 10Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting 11Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 2Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 3Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 4Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 5Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 6Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 7Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 8Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 9Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C 10
ENDOlap™ 25 liter Heated Insufflator
Insufflators
KLEPPINGER bipolar forceps
...thologist to visualize the presence of Human Papil... choice of sample types: tissue, monolayer-based p...ocktails utilize proprietary probe formulations. T... genotypes 16, 18, 31, 33, 35, 39, 51, 52, 56, 58,...
Medicine Products: